多柔比星脂质体在难治性非霍奇金淋巴瘤治疗中的应用  

Application of Liposomal Doxorubicin in the Treatment of Refractory Non-Hodgkin’s Lymphoma

作　　者：蒋慧芳[1] 娄引军[2] 麦文渊[2] 金洁[2] 

机构地区：[1]浙江省立同德医院,杭州310012 [2]浙江大学附属第一医院血液科

出　　处：《医学研究杂志》2008年第8期92-93,共2页Journal of Medical Research

摘　　要：目的观察多柔比星脂质体联合环磷酰胺、长春新碱、泼尼松龙治疗难治性淋巴瘤的临床疗效。方法多柔比星脂质体40mg／m^2，静脉滴注，第1天，环磷酰胺750mg／m^2，静脉注射，第1天，长春新碱2mg，静脉注射，第1天，泼尼松龙100mg／m^2口服第1-5天。每3-4周为1周期，全部病人均不少于2个周期。结果全组13例患者中完全缓解7例，占53．8％，部分缓解4例，占30．76％，无变化2例，占15．35％，9例有B类症状的患者中7例症状全部消失，2例明显改善。不良反应主要是轻度的胃肠道反应和少数患者出现Ⅲ度的骨髓抑制。结论多柔比星脂质体联合环磷酰胺、长春新碱、泼尼松龙治疗难治性淋巴瘤有较好的临床疗效，不良反应不大，是临床值得进一步验证的补救性化疗方案。Objective To observe the efficacy of liposomal doxorubicin combined with cyclophosphamide, vincristine and prednisone in the treatment of refractory Non-Hodgkin＇ s lymphoma. Methods Liposomal doxorubicin （40mg/m^2） was given by intravenous drip in the 1st day. Cyclophosphamide （750mg/m^2） was given by intravenous injection in the 1st day. Vincristine （2mg） was given by intravenous injection in the 1st day. Prednisone （100mg/m^2） was given orally from the 1st to the 5th day. A cycle was repeated every 3 to 4 weeks. Every patient took at least 2 cycles of the regimen. Results A total of 13 patients were assessed in the group. Among them, 7 were completely release （53.8%） , 4 were partially release （30.67%） and 2 remained the same （ 15.35% ）. The B symptom of 7 patients in the 9 with that disappeared, and that of the other 2 patients was improved obviously. The most common adverse effects were slight gastrointestinal reactions and the grade Ⅲ bone marrow suppression in a few patients. Conclusion The regimen of liposomal doxorubicin combined with cyclophosphamide, vincristine and prednisone is effective in the treatment of refractory Non-Hodgkin＇s lymphoma with tolerable toxicity. It may be a salvage chemotherapeutic regimen deserving further study.

关 键 词：多柔比星脂质体 难治性淋巴瘤 临床分析 治疗方法 

分 类 号：R737.33[医药卫生—肿瘤] R733.4[医药卫生—临床医学]